Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Virologically Suppressed People With HIV-1
2024-520159-26-00Phase 2Authorised
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- May 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Baricitinib arm with Placebo arm (2 arms). Primary endpoints: Proportion of participants with Grade 3 or 4 treatment-related adverse events or laboratory abnormalities and Change in levels of pSTAT1, pSTAT3, and pSTAT5 in CD4+ T cells. Planned start May 2025; status: authorised.
02
Drugs
baricitinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-520159-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520159-26-00.